Drug Profile


Alternative Names: Famitinib maleate; SHR 1020

Latest Information Update: 09 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Jiangsu Hengrui Medicine Co.
  • Class Antineoplastics; Diethylamines; Fluorobenzenes; Indoles; Pyrroles; Small molecules
  • Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; Platelet-derived growth factor receptor antagonists; Proto oncogene protein c-kit inhibitors; Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Colorectal cancer; Non-small cell lung cancer
  • Phase II Gastrointestinal stromal tumours; Neuroendocrine tumours; Renal cell carcinoma
  • No development reported Breast cancer; Nasopharyngeal cancer

Most Recent Events

  • 01 Feb 2017 Jiangsu Hengrui Medicine terminates a phase III trial in Non-small cell lung cancer (Late-stage disease, Second-line therapy or greater, Metastatic disease, Recurrent, Combination therapy) due to difficulty in recruitment in China (PO) (NCT02766140)
  • 06 May 2016 Jiangsu Hengrui Medicine plans a phase III trial for Non-small cell lung cancer (Combination therapy, Late-stage disease, Recurrent, Metastatic disease; Second-line therapy or greater) in China (NCT02766140)
  • 01 May 2016 Phase-III clinical trials in Non-small cell lung cancer (Late-stage disease, Second-line therapy or greater, Metastatic disease, Recurrent, Combination therapy) in China (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top